The United States Pharmacopeia has launched Version 6.0 for its MEDMARX program. MEDMARX is an Internet-accessible, anonymous reporting program that allows hospital personnel to voluntarily report, track, and trend data, incorporating nationally standardized data elements. Hospitals subscribe to MEDMARX as part of their internal quality-improvement process. Subscribers can review errors entered by other participants in "real time" and also can view any reported action taken by other institutions in response to an error.
The newest version enables users to track all types of adverse drug events. The adverse-drugreaction element incorporates the Naranjo Probability Assessment, which is a validated tool for determining the odds that a specific reaction is due to a given drug. Other features of MEDMARX 6.0 include the following:
MEDMARX's database currently includes >750,000 records and is expected to exceed 1 million records by early 2005. For more information, visit www.usp.org, or call 877-MEDMARX.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs